It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA, Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council, discusses their importance to patients yesterday, today, and tomorrow. Dr. Cromwell is board-certified in Family Medicine and Clinical Lipidology with over 20 years of clinical research experience. As he … Read more
Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a … Read more
Velocity has made an incredible impact over the past year! Our sites conducted clinical trials that supported 12 U.S. product approvals in 2023, contributing to the betterment of global health. To date, Velocity has contributed to research programs for over 50 product approvals. From pioneering vaccines to cutting-edge drugs, Velocity’s team worldwide has worked diligently … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). According to the NASH education program, … Read more
Six Velocity Principal Investigators coauthored an article recently published in Nature Medicine. The article covers the results of a Phase 2/3 trial of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Beyond yielding promising results, the trial has set the groundwork for swiftly addressing circulating variants as SARS-CoV-2 continues … Read more
After battling on the frontline for many years against an aggressive and elusive opponent, Michael Hemphill, MD and the Velocity team in Savannah, GA, believe we’ve entered an exciting “new era” in the fight against Alzheimer’s disease and dementia. Velocity conducts clinical trials related to disorders of the nervous system in Savannah as an embedded research … Read more
Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults. Alzheimer’s disease, a cruel and pernicious affliction, is a brain disorder that slowly destroys memory, thinking skills, and eventually, the ability to carry out even the most simple and … Read more
Inc. magazine ranked Velocity Clinical Research 543 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Durham, NC, Velocity is the world’s leading integrated site organization with 80 sites worldwide. This is Velocity’s first recognition on the list. Paul Evans, President and CEO of Velocity Clinical … Read more
Velocity is collaborating with Merck to explore a new way to engage communities about clinical research. Starting this month the Velocity team members are conducting a tour of several Southern California cities, using Merck’s iLab53, a state-of-the-art, modular 39-foot mobile research unit to reach underserved communities. At each stop, the mobile research unit will serve … Read more
Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, and Privia Health (Nasdaq: PRVA), a physician enablement company serving more than 3,700 providers and 4.4 million patients, today announced a partnership to open embedded clinical research sites within Privia’s practice network. The partnership is intended to establish integrated research sites within existing Privia Care … Read more